Trial Information
Current as of March 23, 2025
Completed
Keywords
ClinConnect Summary
BACKGROUND:
The adult respiratory distress syndrome (ARDS) is a multifactorial disorder most commonly occurring secondary to sepsis syndrome. Sepsis syndrome occurs in 250,000 to 500,000 patients per year with approximately one-third of these developing ARDS and other organ failures. Extensive studies utilizing the sheep endotoxin model of ARDS as well as data from human pilot studies suggest that cyclooxygenase inhibitors (in particular, ibuprofen) would be useful in the prevention and reversal of many of the pathophysiological abnormalities related to sepsis. Animal studies where ibuprof...
Gender
ALL
Eligibility criteria
- • Men and women patients with known or suspected sites of serious infection if core temperature was 38.3 degrees Celsius, heart rate 90 in the absence of beta-blockers, respiratory rate 20 or minute ventilation 10 liters per minute. In addition, one o
Trial Officials
Gordon Bernard
Vanderbilt University
About Vanderbilt University
Vanderbilt University is a prestigious research institution renowned for its commitment to advancing healthcare through innovative clinical trials and translational research. With a strong emphasis on collaboration across various disciplines, Vanderbilt leverages its state-of-the-art facilities and a diverse team of experts to conduct rigorous clinical studies. The university is dedicated to improving patient outcomes by exploring novel therapeutic interventions and enhancing understanding of disease mechanisms. Through its robust clinical research infrastructure, Vanderbilt University aims to contribute significantly to the scientific community and the development of effective healthcare solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
Similar Trials